**Vitamin D status in irritable bowel syndrome and the impact of supplementation on symptoms: a systematic review and meta-analysis**

*Estado de la vitamina D en el síndrome del intestino irritable y el impacto de la suplementación en los síntomas: una revisión sistemática y metaanálisis*

Bin Yang, Kang Liao, Lili Yuan

Third Hospital of Shanxi Medical University. Shanxi Bethune Hospital. Shanxi Academy of Medical Sciences. Tongji Shanxi Hospital. Taiyuan, People’s Republic of China

**Abstract**

**Background:** latest studies have shown that vitamin D deficiency is related to the occurrence of irritable bowel disease (IBS), and taking vitamin D as a supplement can alleviate the symptoms of irritable bowel disease. However, clinical treatment of irritable bowel disease with vitamin D is controversial.

**Objective:** we conducted a meta-analysis of all clinical trials to evaluate the associations between vitamin D and irritable bowel disease.

**Methods:** we screened all randomized controlled trials that were published before December 20, 2021 from the following databases: Medline, Web of Science, China National Knowledge Infrastructure (CNKI), Cochrane Central, and Clinical Trial. We used RevMan 5.4.1 and StatA 16.1 to analyze the relevant data. The standardized mean difference (SMD) with 95% confidence interval (95% CI) was used to report effect sizes. Serum vitamin D concentration, risk of vitamin D deficiency among patients with IBS, Symptom Severity Score (SSS), and Quality of Life (QoL) score are the main endpoint outcomes in this study.

**Results:** data from twelve clinical trials with 1331 IBS patients were included. Patients with IBS have relatively low vitamin D levels in their serum. Vitamin D supplementation improves the Quality of Life (QoL) score but has no significant effect on the Symptom Severity Score (SSS).

**Conclusions:** vitamin D deficiency is associated with the pathogenesis of irritable bowel syndrome. Serum vitamin D levels decreased in patients with irritable bowel syndrome, and vitamin D supplementation could improve patient quality of life.

**Keywords:** Vitamin D. Irritable bowel syndrome. Meta-analysis. Gastroenterology.

**Resumen**

**Antecedentes:** los últimos estudios han demostrado que la deficiencia de vitamina D está relacionada con la aparición de la enfermedad del intestino irritable (SII) y que tomar vitamina D como suplemento puede aliviar los síntomas de la enfermedad del intestino irritable. Sin embargo, el tratamiento clínico de la enfermedad del intestino irritable con vitamina D es controvertido.

**Objetivo:** se realizó un metaanálisis de todos los ensayos clínicos para evaluar las asociaciones entre la vitamina D y la enfermedad del intestino irritable.

**Métodos:** se examinaron todos los ensayos controlados aleatorios que se publicaron antes del 20 de diciembre de 2021 en las siguientes bases de datos: Medline, Web of Science, China National Knowledge Infrastructure (CNKI), Cochrane Central y Clinical Trial. Se utilizaron RevMan 5.4.1 y StatA 16.1 para analizar los datos relevantes. Se utilizó la diferencia de medias estandarizada (DME) con intervalo de confianza del 95% (IC 95%) para presentar los tamaños del efecto. La concentración sérica de vitamina D, el riesgo de deficiencia de vitamina D entre los pacientes con SII, la puntuación de gravedad de los síntomas (SSS) y la puntuación de calidad de vida (CdV) son los principales criterios de valoración de este estudio.

**Resultados:** se incluyeron datos de doce ensayos clínicos en 1331 pacientes con SII. Los pacientes con SII tienen niveles relativamente bajos de vitamina D en su suero. La suplementación con vitamina D mejora la puntuación de calidad de vida (CdV), pero no tiene un efecto significativo en la puntuación de gravedad de los síntomas (SSS).

**Conclusiones:** la deficiencia de vitamina D se asocia con la patogénesis del síndrome del intestino irritable. Los niveles séricos de vitamina D disminuyeron en pacientes con síndrome del intestino irritable, y la suplementación con vitamina D podría mejorar la calidad de vida de los pacientes.

**Palabras clave:** Vitamina D. Síndrome del intestino irritable. Metaanálisis. Gastroenterología.

Received: 19/01/2022 • Accepted: 16/03/2022

Funding: this study had no funding support.

Conflicts of interest: there are no conflicts of interest.


DOI: http://dx.doi.org/10.20960/nh.04044

Copyright 2022 SENPE y Arán Ediciones S.L. Este es un artículo Open Access bajo la licencia CC BY-NC-SA (http://creativecommons.org/licenses/by-nc-sa/4.0/).
INTRODUCTION

BACKGROUND AND AVAILABLE EVIDENCE

Irritable bowel syndrome (IBS) is one of the common functional gastrointestinal diseases (1,2). With the deepening of research and the improvement of medical workers’ understanding of the disease, the diagnostic rate of IBS has also increased. According to the latest Rome IV standard, irritable bowel syndrome is a non-organic disease characterized by abdominal pain with changes in bowel habits or stool traits (3-5). The prevalence of IBS in Chinese people is about 6.5 % and is on the rise. The possible pathogenesis of IBS includes visceral hypersensitivity, changes in gastrointestinal motility, abnormal regulation of brain and intestinal axis, intestinal flora disorder, mental and psychological factors, and a regulatory mechanism of the nerve-immune-endocrine network that has attracted attention in recent years has been reported (6). Treatment of IBS emphasizes individualized comprehensive treatment, including psychological and behavioral intervention, diet adjustment, and drug therapy, but the overall treatment effect is unsatisfactory, seriously affecting the quality of life of patients, bringing heavy psychological and social burdens. Therefore, it is urgent to explore safe and effective new therapies for IBS treatment (7,8). The main function of vitamin D is to regulate calcium and phosphorus metabolism, but new ideas suggest that vitamin D can inhibit inflammation and regulate immune response (9). Vitamin D deficiency occurs in 30 to 50 % of the global human population and also accounts for a similar proportion in people with gastrointestinal diseases. Recent studies have found that the serum vitamin D level in IBS patients is significantly lower than that in healthy people. Vitamin D deficiency (VDD) has a high incidence in IBS patients, but the relationship between vitamin D and the severity of gastrointestinal symptoms in IBS patients is not clear (10). In recent years, foreign cases and small-sample clinical studies have reported that vitamin D supplementation may alleviate clinical symptoms in IBS patients (11,12). Our initial intention in this review is to synthesize existing studies to provide solid evidence for vitamin D in the treatment of IBD.

VALUE OF THIS REVIEW

In the United States, the medical costs for IBS are as high as $20 billion a year. The current treatment regimen is unsatisfactory, seriously affecting the quality of life of patients, bringing heavy psychological and social burdens. Therefore, it is urgent to explore safe and effective new therapies for the treatment of IBS.

METHOD

SEARCH STRATEGY

We selected all randomized controlled trials associated with vitamin D and irritable bowel syndrome from the following databases: Medline, Web of Science, CNKI, Cochrane Central, and Clinical Trial, and any limitations of language were rejected. We also searched the references of earlier meta-analyses related to the selected studies to determine any additional potential studies. The trials were limited to human studies.

STUDY SELECTION

Two independent and trained reviewers screened the title/abstract and full text to determine the included literature. The different opinions between reviewers would be solved by another experienced doctor. The criteria for excluding literature were as follows: 1) the study was performed on randomized controlled trials; 2) participants received at least 3,000 IU of vitamin D per day for 4 weeks; 3) enrollment of patients with no organic digestive diseases; 4) data are complete or available; 5) any conference papers, reviews, case reports, experience summaries, and repeated literature (only the earliest one is retained in the papers published in multiple languages) were also rejected.

ASSESSMENT OF RISK OF BIAS

Two experienced reviewers used Revman 5.4.1 (RevMan; The Cochrane Collaboration, Oxford, UK) to evaluate the publication bias of articles according to the Cochrane Handbook for Systematic Reviews of Interventions. Quality evaluation was generated in the following assessments: 1) random sequence generation; 2) allocation concealment; 3) blinding of participants and personnel; 4) blinding of outcome assessment; 5) incomplete outcome data; 6) selective reporting; 7) other biases. A summary of bias risks is provided in figure 1.

DATA EXTRACTION

Two reviewers assessed and extracted relevant data independently, including demographic characteristics of participants, clinical diagnosis types, treatment duration, type and dose of administration, and sample size. We summarized the curative effect of vitamin D on irritable bowel syndrome (IBS) in the following measures: 1) risk of vitamin D deficiency among patients with IBS; 2) SSS; 3) QoL; 4) serum vitamin D concentration. These outcomes were summarized in figures 2 A-D.

STATISTICAL ANALYSIS

Each outcome was represented by using standardized mean difference (SMD) with a 95 % confidence interval (CI). In addition, a sensitivity analysis was carried out when necessary. We used the STATA software (Stata Corporation, College Station, TX) to perform forest plot graphics and funnel plots. All statistical tests were bilateral significant levels; p-value was set at 0.05. Q-statistic and I^2 test were used to calculate the heterogeneity of all studies. When p-value is less than 0.1 or I^2 is bigger than
40%, heterogeneity is considered to be significant, and we used a random effects model. On the contrary, when p is bigger than 0.1 or I² is less than 40%, we used the fixed-effect model.

Publication bias was evaluated with a funnel plot, Egger’s test, and Begg’s test. Egger’s and Begg’s linear regression tests were used to evaluate asymmetry, and the level of significance was set as p < 0.05 (Fig. 3 A-D).

Three researchers (Bin Yang, Lili Yuan, and Kang Liao) independently conducted the screening of titles, abstracts, and the full text of all studies. Study exclusion and inclusion were based on the criteria we set before. Two reviews (Bin Yang, Lili Yuan) extracted the relevant data from included studies: characteristics of participants, outcomes measures, treatment duration, etc., and quality assessments of the studies were performed according to the Cochrane Handbook for Systematic Reviews of Interventions. Any disagreement was reported to an experienced doctor. Another researcher double-checked the consistency between the statistical results converted into software and the data provided in the original literature to avoid any wrong inputs. One reviewer (Bin Yang) performed the statistical analysis using STATA16.1 to obtain the results of each outcome. The whole process was under the guidance of the Cochrane Handbook. All patient data were derived from published literature.

RESULTS

SELECTION OF STUDIES

The literature retrieval strategy is shown in Annex 1. We identified a total of 793 studies associating vitamin D and irritable bowel syndrome (IBS), from which we ultimately included a total of 12 RCTs in 1331 patients, and details of these studies are shown in table I (13-23). Any studies that did not meet the criteria were excluded. We provide a flow chart for the progress of literature retrieval and the inclusion or exclusion of studies in figure 4. The risk of bias of all included trials was assessed using the Cochrane method.

META-ANALYSIS

Risk of vitamin D deficiency among patients with IBS

A total of 974 patients were enrolled in three studies, which provide the risk of vitamin D deficiency among patients with IBS. Data show that people with vitamin deficiency are more likely to suffer from irritable bowel syndrome (relative risk RR = 1.78, 95% CI [1.45, 2.12]). The heterogeneity test for the included studies was done by STATA
16.1, and results showed $p = 0.000$ and $I^2 = 91.5\%$, a very high heterogeneity, for which we decided to use the random effect model. The results were summarized in figure 2A and the result of publication biases is shown in figure 3A.

**Serum vitamin D concentration**

Nine studies including 1331 samples reported serum vitamin D levels in patients with irritable bowel syndrome and controls. After summarizing the data, we found that serum vitamin D levels in patients with irritable bowel syndrome were significantly lower than those in the control group (SMD, -0.84, 95 % CI [-0.18, -0.50]). We used STATA 16.1 to test the heterogeneity of 9 studies, and the results showed that $p = 0.000$, $I^2 = 81\%$, indicating high heterogeneity, for which a random effect model is needed. Revman 5.4.1 (Revman 2020) provided a forest plot for each outcome measure. The results were summarized in figure 2B and the result of publication bias is shown in figure 3B.

**The SS scores**

Five studies enrolling 536 participants reported the effect of vitamin D supplementation on the SS score in patients with IBS. The forest plot showed that vitamin D supplementation had no significant effect on SS score in IBS patients (SMD, -0.43, 95 % CI [-0.89, 0.03]). The heterogeneity test included in the study was carried out by STATA1 6.1, where $p = 0.000$, $I^2 = 85.6\%$, a very high heterogeneity than that we previously set. The source of heterogeneity may be the insufficient number of included studies and small sample size. The publication bias of these 5 studies was done by STATA 16.1. These results are summarized in figure 2 and the result of publication bias is shown in figure 3C.

**The QoL score**

A total of 448 people in the four studies reported the effect of vitamin D supplementation on QoL scores of patients with IBS.
The summarized data of four studies show that vitamin D supplementation can significantly increase the QoL score of IBS patients (SMD, 0.65, 95% CI [0.14, 1.15]), which means that the quality of life of patients is significantly improved. We underwent the heterogeneity test for the 4 studies by STATA 16.1, in which $p = 0.000$ and $I^2 = 85.6\%$, a very high heterogeneity, and for which we decided to use the random effect model. The results were summarized in figure 2D and the result of publication bias is shown in figure 3D.

**DISCUSSION**

Although the pathogenesis of IBS has not been fully understood, many scholars believe that functional bowel disease is caused by multiple factors. The recognized pathogenesis of IBS is as follows: gastrointestinal motility disorder, visceral sensitivity abnormality, poor food tolerance, intestinal immune system abnormality, and bacterial-intestinal-brain axis dysfunction (25,26). In addition, social-psychological factors, dietary habits, intestinal flora imbalance, intestinal infection, abnormal endogenous cannabinoid system, and vitamin D deficiency are closely related to IBS. Vitamin D deficiency has become a research hotspot (12,27-29).

Vitamin D is an essential vitamin for the human body and belongs to the fat-soluble vitamins group. In addition to the regulation of calcium and phosphorus balance, vitamin D also has anti-inflammatory and immune regulatory effects. Many studies suggest that vitamin D deficiency is widespread in IBS patients (30,31). In addition, a retrospective study of children and adolescents in the United States found that compared with the control group, IBS patients have lower 25(OH)D concentrations. Only 7% of IBS children and adolescents have sufficient vitamin D.

Figure 3.
Publication bias of each outcome. The effect sizes were pooled by using the random-effects model. The standardized mean difference and standard error are described in this funnel plot. The black circles are published literature, and the cone region surrounded by virtual lines on both sides represents the 95% confidence interval. A. Risk of vitamin D deficiency among patients with IBS. B. Serum vitamin D levels of IBS patients and controls. C. Changes in SSS scores of patients after vitamin D treatment. D. Changes in QoL of patients after vitamin D treatment.
### Table I. Systematic review of RCTs of vitamin D for irritable bowel disease

<table>
<thead>
<tr>
<th>First author</th>
<th>Country</th>
<th>Sample size</th>
<th>The follow-up time</th>
<th>Course of disease</th>
<th>Gender</th>
<th>Trial group age</th>
<th>Control group age</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td>Year</td>
<td>ALL</td>
<td>T</td>
<td>C</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>A. Abbasnezhad (13)</td>
<td>Iran</td>
<td>2016</td>
<td>85</td>
<td>44</td>
<td>41</td>
<td>6 months</td>
<td>-</td>
</tr>
<tr>
<td>Benjamin Udoka Nwosu (14)</td>
<td>USA</td>
<td>2017</td>
<td>171</td>
<td>55</td>
<td>116</td>
<td>78 months</td>
<td>9 months</td>
</tr>
<tr>
<td>Claire E. Williams (15)</td>
<td>England</td>
<td>2021</td>
<td>135</td>
<td>68</td>
<td>67</td>
<td>28 months</td>
<td>3 months</td>
</tr>
<tr>
<td>Doaa El Amrousy (16)</td>
<td>Egypt</td>
<td>2018</td>
<td>112</td>
<td>56</td>
<td>56</td>
<td>24 months</td>
<td>6 months</td>
</tr>
<tr>
<td>Elif Borekci (17)</td>
<td>Turkey</td>
<td>2021</td>
<td>154</td>
<td>75</td>
<td>79</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Sijing Huang (18)</td>
<td>China</td>
<td>2019</td>
<td>119</td>
<td>61</td>
<td>58</td>
<td>9 months</td>
<td>-</td>
</tr>
<tr>
<td>Mahsa Jalili (19)</td>
<td>Iran</td>
<td>2019</td>
<td>116</td>
<td>58</td>
<td>58</td>
<td>-</td>
<td>1.5 months</td>
</tr>
<tr>
<td>Masoumeh Khalighi Sikaroudi (20)</td>
<td>Iran</td>
<td>2020</td>
<td>88</td>
<td>44</td>
<td>44</td>
<td>15 months</td>
<td>-</td>
</tr>
<tr>
<td>Simon Tazzyman (21)</td>
<td>England</td>
<td>2017</td>
<td>51</td>
<td>17+16</td>
<td>18</td>
<td>3 months</td>
<td>-</td>
</tr>
<tr>
<td>Claire Williams (22)</td>
<td>England</td>
<td>2019</td>
<td>80</td>
<td>15</td>
<td>65</td>
<td>3 months</td>
<td>-</td>
</tr>
<tr>
<td>YASIR KHAYAT (23)</td>
<td>Saudi Arabia</td>
<td>2015</td>
<td>160</td>
<td>60</td>
<td>100</td>
<td>3 months</td>
<td>-</td>
</tr>
<tr>
<td>Huiling Yu (24)</td>
<td>China</td>
<td>2016</td>
<td>60</td>
<td>30</td>
<td>30</td>
<td>15 months</td>
<td>-</td>
</tr>
</tbody>
</table>

The 26 trials included in this meta-analysis were randomized controlled trials. They were summarized as participants’ country, sample size, gender, and age. Data were reported in means and standard deviations (SD). T: trial; C: control; USA: United States of America.
More than half of IBS patients have vitamin D deficiency, which may be caused by dietary restriction, sunlight exposure, living habits, gender, hypoproteinemia, and other factors (32,33). Individuals can acquire exogenous vitamin D from foods rich in vitamin D, but more vitamin D3 (about 70%) is produced in the skin under ultraviolet light. If the yield from the skin is sufficient, it can even make individuals no longer need to take it from food. The prevalence of vitamin D deficiency in IBS patients may be associated with excessive indoor activity time and sunscreen habits inspired by concerns about the risk of skin cancer caused by exposure to ultraviolet light. These habits affect the normal outdoor activity time of individuals to some extent, resulting in insufficient sources of vitamin D. In conclusion, increasing outdoor activities, ensuring adequate sunshine hours, and appropriate supplementation of vitamin D supplements can provide new ideas for the prevention and treatment of IBS (20,34).

Epidemiological surveys have shown that the prevalence of IBS varies in different regions, different countries, and even within the same country, which may be due to different survey populations and different survey methods. The long course of IBS consumes a lot of medical resources, which seriously affects the quality of life of IBS patients and their families, and causes a serious social burden (35,36). Therefore, it is of great significance for the prevention of IBS to actively carry out an epidemiological investigation and follow-up of IBS for various populations and to promote the health of IBS-related knowledge and health education. Although the pathogenesis of IBS is still unclear, an in-depth study of the pathogenic factors can provide valuable direction for the prevention and treatment of IBS.

We have included four outcome measures from twelve studies and 1331 patients in this review, from which we summarized the following evidence: vitamin D deficiency is a risk factor for irritable bowel syndrome (RR, 1.76, 95% CI [1.45, 2.12]) and serum vitamin D levels in patients with irritable bowel syndrome are significantly lower than in normal people (SMD, -0.84, 95% CI [-1.18, 0.50]). In addition, vitamin D supplementation in patients with irritable bowel syndrome can significantly improve their quality of life (SMD, 0.65, 95% CI [0.14, 1.15]). However, vitamin D supplementation had no significant effect on the SS score of patients with irritable bowel syndrome (SMD, -0.43, 95% CI [-0.89, 0.03]).

Finally, we concluded that vitamin D deficiency is associated with irritable bowel syndrome: vitamin D deficiency patients are more likely to suffer from irritable bowel syndrome, taking vitamin D can improve the quality of life of patients with irritable bowel syndrome. Currently, serum 25(OH)D value is used as an indicator of vitamin D level internationally, for which the universally accepted criteria are that serum 25(OH)D < 20 ng/mL is considered as vitamin D deficiency, serum 25(OH)D between 20 and 30 ng/mL as vitamin D insufficiency, and serum 25(OH)D ≥ 30 ng/mL as vitamin D sufficiency (37). In addition to the IBS studied in this paper, vitamin D levels are also closely related to the skeletal, muscular, and cardiovascular systems. A minimum serum 25(OH)D concentration of 20 ng/mL should be achieved in the general population, and 30 ng/mL should be maintained in high-risk groups to ensure bone health (38). In addition, vitamin D is associated with maintaining muscle function and reducing the risk of cardiovascular diseases, for which the optimal vitamin D levels are not yet clear.
CONCLUSIONS

Vitamin D deficiency is associated with the pathogenesis of irritable bowel syndrome. Serum vitamin D levels decreased in patients with irritable bowel syndrome, and vitamin D supplementation could improve the quality of life of patients.

ANNEX 1. THE SEARCH STRATEGY

<table>
<thead>
<tr>
<th>Number</th>
<th>PubMed Search strategy</th>
</tr>
</thead>
<tbody>
<tr>
<td>#1</td>
<td>irritable bowel syndrome (Mesh)</td>
</tr>
<tr>
<td>#2</td>
<td>Irritable Bowel Syndromes (Title/Abstract)</td>
</tr>
<tr>
<td>#3</td>
<td>Syndrome, Irritable Bowel (Title/Abstract)</td>
</tr>
<tr>
<td>#4</td>
<td>Syndromes, Irritable Bowel (Title/Abstract)</td>
</tr>
<tr>
<td>#5</td>
<td>Colon, Irritable (Title/Abstract)</td>
</tr>
<tr>
<td>#6</td>
<td>Irritable Colon (Title/Abstract)</td>
</tr>
<tr>
<td>#7</td>
<td>Colitis, Mucous (Title/Abstract)</td>
</tr>
<tr>
<td>#8</td>
<td>Colitis, Mucous (Title/Abstract)</td>
</tr>
<tr>
<td>#9</td>
<td>Mucous Colitis (Title/Abstract)</td>
</tr>
<tr>
<td>#10</td>
<td>Mucous Colitis (Title/Abstract)</td>
</tr>
<tr>
<td>#11</td>
<td>#1 OR #2 OR #3 OR #4 OR #5 OR #6 OR #7 OR #8 OR #9 OR 10</td>
</tr>
<tr>
<td>#12</td>
<td>Postprandial distress syndrome (Mesh)</td>
</tr>
<tr>
<td>#13</td>
<td>#11 AND #12</td>
</tr>
</tbody>
</table>

REFERENCES

12. Williams CE, Williams EA, Corfe BM. Vitamin D status in irritable bowel syndrome and the impact of supplementation on symptoms: what do we know and what do we need to know? Eur J Clin Nutr 2018;72(10):1385-63. DOI: 10.1038/s41430-017-0064-z


